Background: ELL-associated factor 2 (EAF2) acts as a transcriptional transactivator of TCEA1 elongation activity. It is also a transcriptional transactivator of ELL (eleven nineteen lysine-rich leukemia) 1 and ELL2 elongation activities. EAF2 has been shown to be a potent inducer of apoptosis in prostatic and non-prostatic cell lines and to inhibit prostate tumor growth in vivo [taken from the Universal Protein Resource (UniProt) Q96CJ1].